Department of Cardiothoracic Surgery, Royal Perth Hospital, Perth, WA 6000, Australia.
Heart Lung Circ. 2012 Apr;21(4):229-30. doi: 10.1016/j.hlc.2011.09.007. Epub 2011 Oct 28.
Recombinant Factor VII (Novoseven) is gaining recognition as an established treatment option for post-cardiac surgery bleeding. However, little information is available on its use in patients being maintained on Extra-Corporeal Membrane Oxygenation (ECMO) support, particularly in the adult population. We present the first case of the successful use of Factor VIIa to control bleeding in an adult patient on ECMO post cardiac surgery.
重组因子 VII（诺维赞）作为心脏手术后出血的既定治疗选择，正逐渐得到认可。然而，关于其在接受体外膜肺氧合（ECMO）支持的患者中的应用，特别是在成年人群中的应用，信息有限。我们报告了首例在心脏手术后接受 ECMO 的成年患者中成功使用因子 VIIa 控制出血的病例。
